GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sunflower Pharmaceutical Group Co Ltd (SZSE:002737) » Definitions » ROC %

Sunflower Pharmaceutical Group Co (SZSE:002737) ROC % : 13.88% (As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Sunflower Pharmaceutical Group Co ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Sunflower Pharmaceutical Group Co's annualized return on capital (ROC %) for the quarter that ended in Sep. 2024 was 13.88%.

As of today (2025-03-30), Sunflower Pharmaceutical Group Co's WACC % is 6.67%. Sunflower Pharmaceutical Group Co's ROC % is 35.10% (calculated using TTM income statement data). Sunflower Pharmaceutical Group Co generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Sunflower Pharmaceutical Group Co ROC % Historical Data

The historical data trend for Sunflower Pharmaceutical Group Co's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunflower Pharmaceutical Group Co ROC % Chart

Sunflower Pharmaceutical Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.37 23.91 27.42 31.36 39.91

Sunflower Pharmaceutical Group Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.01 44.13 45.60 40.64 13.88

Sunflower Pharmaceutical Group Co ROC % Calculation

Sunflower Pharmaceutical Group Co's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=1299.482 * ( 1 - 14.01% )/( (3179.172 + 2420.257)/ 2 )
=1117.4245718/2799.7145
=39.91 %

where

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=7031.747 - 1166.884 - ( 3847.391 - max(0, 2175.369 - 4861.06+3847.391))
=3179.172

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=6881.913 - 1193.607 - ( 3602.114 - max(0, 1519.915 - 4787.964+3602.114))
=2420.257

Sunflower Pharmaceutical Group Co's annualized Return on Capital (ROC %) for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=429.008 * ( 1 - 14.34% )/( (2497.787 + 2797.434)/ 2 )
=367.4882528/2647.6105
=13.88 %

where

Invested Capital(Q: Jun. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=6250.954 - 1248.321 - ( 2504.846 - max(0, 1290.159 - 4229.16+2504.846))
=2497.787

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5931.721 - 935.29 - ( 2198.997 - max(0, 980.677 - 3920.333+2198.997))
=2797.434

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sunflower Pharmaceutical Group Co  (SZSE:002737) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Sunflower Pharmaceutical Group Co's WACC % is 6.67%. Sunflower Pharmaceutical Group Co's ROC % is 35.10% (calculated using TTM income statement data). Sunflower Pharmaceutical Group Co generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Sunflower Pharmaceutical Group Co ROC % Related Terms

Thank you for viewing the detailed overview of Sunflower Pharmaceutical Group Co's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Sunflower Pharmaceutical Group Co Business Description

Traded in Other Exchanges
N/A
Address
Welcome Road, 18 East Lake Road, Harbin High-Tech Industrial Development Zone, Harbin, Heilongjiang, CHN
Sunflower Pharmaceutical Group Co Ltd is engaged in pharmaceutical manufacturing, marketing, and scientific research. The company's product profile include Honeysuckle, Weikangling Granules, Autumn pear moisturizing cream, Vitamin AD drops, Pediatric paracetamol granules, Jianweixiaoshi tablets, Pediatric Chai Gui Antipyretic Granules, Pediatric cough syrup, Kang Fu anti-inflammatory suppository, Xiangsha Yangwei Pills, and others.
Executives
Zhou Jian Zhong Executives
Liu Tian Wei Director
Guan Yu Xiu Director
Wu Guo Xiang Executives
Ren Jing Shang Directors, executives
Guan Yan Bin Directors, executives
Wan Yun Guo Executives
Tian Yan Secretary Dong
Tan Chang Executives
Zhang Quan Director
Xu Qing Fen Supervisors
Jiang Feng He Supervisors
Wu Shu Hua Director
Guan Yan Ling Director

Sunflower Pharmaceutical Group Co Headlines

No Headlines